Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Connect with investors, share insights, and grow together
Stay up to date on latest investing trends and other announcements
Explore our range of financial tools to streamline your investment planning
A structured, comprehensive way to understand global investing
Read about our journey and get to know the leadership team at Vested
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. more
| Time Frame | ONTX | S&P500 |
|---|---|---|
| 1-Week Return | - | -1.8% |
| 1-Month Return | - | -2.08% |
| 3-Month Return | - | 11.56% |
| 6-Month Return | - | 6.43% |
| 1-Year Return | - | 20.72% |
| 3-Year Return | 2749.04% | 69.79% |
| 5-Year Return | 314.41% | 71.71% |
| 10-Year Return | -97.61% | 269.13% |
| Time Frame | ONTX | S&P500 |
|---|---|---|
| 1-Week Return | 0.00% | -61.21% |
| 1-Month Return | 0.00% | -22.57% |
| 3-Month Return | 0.00% | 55.84% |
| 6-Month Return | 0.00% | 13.47% |
| 1-Year Return | 0.00% | 20.72% |
| 3-Year Return | 205.42% | 19.30% |
| 5-Year Return | 32.89% | 11.42% |
| 10-Year Return | -31.16% | 13.95% |
| Sector | Weight |
|---|---|
|
Health Care
|
100.00% |
Onconova Therapeutics Inc (ONTX) share price today is $28.841.
Yes, Indians can buy shares of Onconova Therapeutics Inc (ONTX) on Vested. To buy ONTX from India, you can open a US Brokerage account by signing up on Vested. The account opening process is completely digital and secure, and takes 3-5 minutes to complete.
Yes, you can purchase fractional shares of Onconova Therapeutics Inc (ONTX) on Vested. You can start investing in Onconova Therapeutics Inc (ONTX) with a minimum investment of $1.
The 52-week high price of Onconova Therapeutics Inc (ONTX) is $. The 52-week low price of Onconova Therapeutics Inc (ONTX) is $.
The stock symbol (or ticker) of Onconova Therapeutics Inc is ONTX.
Yes, you can setup SIP in Onconova Therapeutics Inc shares. Follow the below steps to create the SIP:
Here is the historical performance of ONTX on the Vested app.
The expense ratio of Onconova Therapeutics Inc (ONTX) is .
Link copied